Glycome as biomarkers

General Methods in Biomarker Research and their Applications

Volumn 1-2, Issue , 2015, Pages 111-140

  Shinohara, Yasuro ^a   Furukawa, Jun Ichi ^a   Miura, Yoshiaki ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Vaupell Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84958697813     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-7696-8_23     Document Type: Chapter

References (74)

1. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812-7.
2. Angata T, Fujinawa R, Kurimoto A, et al. Integrated approach toward the discovery of glycobiomarkers of inflammation-related diseases. Ann N Y Acad Sci. 2012;1253:159-69.
3. Arnold JN, Saldova R, Hamid UM, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008;8:3284-93.
4. Badcock G, Pigott C, Goepel J, et al. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 1999;59:4715-9.
5. Bang AG, Carpenter MK. Characteristics and characterization of human pluripotent stem cells. In: Lanza R, Gearhart J, Hogan B, et al., editors. Essentials of stem cell biology. 2nd ed. San Diego: Elsevier; 2009. Chapter 38, p. 339-343.
6. Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066-78.
7. Bennun SV, Yarema KJ, Betenbaugh MJ. Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol. 2013;9:e1002813.
8. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-Linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia. 2001;6:355-64.
9. Carlson DM. Structures and immunochemical properties of oligosaccharides isolated from pig submaxillary mucins. J Biol Chem. 1968;243:616-26.
10. Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, et al. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 2009;27:797-9.
11. Dell A, Morris HR. Glycoprotein structure determination by mass spectrometry. Science. 2001;291:2351-6.
12. Fanayan S, Hincapie M, Hancock WS. Using lectins to harvest the plasma/serum glycoproteome. Electrophoresis. 2012;33:1746-54.
13. Fogli A, Merle C, Roussel V, et al. CSF N-glycan profiles to investigate biomarkers in brain developmental disorders: application to leukodystrophies related to eIF2B mutations. PLoS One. 2012;7:e42688.
14. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet. 2006;7:537-51.
15. Freeze HH, Eklund EA, Ng BG, et al. Neurology of inherited glycosylation disorders. Lancet Neurol. 2012;11:453-66.
16. Fujitani N, Furukawa J, Araki K, Fujioka T, Takegawa Y, Piao J, Nishioka T, Tamura T, Nikaido T, Ito M, Nakamura Y, Shinohara Y. Total cellular glycomics allows characterizing cells and streamlining the discovery process for cellular biomarkers. Proc Natl Acad Sci U S A. 2013;110:2105-10.
17. Furukawa J, Shinohara Y, Kuramoto H, et al. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal Chem. 2008;80:1094-101.
18. Furukawa J-I, Fujitani N, Araki K, et al. A versatile method for analysis of serine/threonine posttranslational modifications by β-elimination in the presence of pyrazolone analogues. Anal Chem. 2011;83:9060-7.
19. Furukawa J, Fujitani N, Shinohara Y. Recent advances in cellular glycomic analyses. Biomolecules. 2013;3:198-225.
20. Gilgunn S, Conroy PJ, Saldova R, et al. Aberrant PSA glycosylation-a sweet predictor of prostate cancer. Nat Rev Urol. 2013;10:99-107.
21. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 1999;45:630-7.
22. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381:107-13.
23. Guillard M, Morava E, van Delft FL, et al. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin Chem. 2011;57:593-602.
24. Hasehira K, Tateno H, Onuma Y, Ito Y, Asashima M, Hirabayashi J. Structural and quantitative evidence for dynamic glycome shift upon production of human induced pluripotent stem cells. Mol Cell Proteomics. 2012;11:1913-23.
25. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev. 2013;42:4443-58.
26. Ikeda K, Shimizu T, Taguchi R. Targeted analysis of ganglioside and sulfatide molecular species by LC/ESI-MS/MS with theoretically expanded multiple reaction monitoring. J Lipid Res. 2008;49:2678-89.
27. Jang H, Kim TW, Yoon S, Choi SY, Kang TW, Kim SY, Kwon YW, Cho EJ, Youn HD. O-GlcNAc regulates pluripotency and reprogramming by directly acting on core components of the pluripotency network. Cell Stem Cell. 2012;11:62-74.
28. Kannagi R, Cochran NA, Ishigami F, et al. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 1983a;2:2355-61.
29. Kannagi R, Levery SB, Ishigami F, et al. New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J Biol Chem. 1983b;258:8934-42.
30. Kobata A, Endo T. Immobilized lectin columns: useful tools for the fractionation and structural analysis of oligosaccharides. J Chromatogr. 1992;597:111-22.
31. Kodama T, Togawa T, Tsukimura T, et al. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease. PLoS One. 2011;6:e29074.
32. Kornak U, Reynders E, Dimopoulou A, et al. Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet. 2008;40:32-4.
33. Krishnamoorthy L, Mahal LK. Glycomic analysis: an array of technologies. ACS Chem Biol. 2009;4:715-32.
34. Kuno A, Uchiyama N, Koseki-Kuno S, et al. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods. 2005;2:851-6.
35. Lauc G, Essafi A, Huffman JE, et al. Genomics meets glycomics - the first GWAS study of human N-glycome identifies HNF1a as a master regulator of plasma protein fucosylation. PLoS Genet. 2010;6:e1001256.
36. Lauc G, Huffman JE, Pučić M, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9:e1003225.
37. Lawrence R, Brown JR, Al-Mafraji K, et al. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol. 2012;8:197-204.
38. Lee JB, Kim JM, Kim SJ, et al. Comparative characteristics of three human embryonic stem cell lines. Mol Cells. 2005;19:31-8.
39. Lefeber DJ, Morava E, Jaeken J. How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis. 2011;34:849-52.
40. Liang YJ, Kuo HH, Lin CH, et al. Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc Natl Acad Sci U S A. 2010;107:22564-9.
41. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-56.
42. Ly M, Laremore TN, Linhardt RJ. Proteoglycomics: recent progress and future challenges. OMICS. 2010;14:389-99.
43. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 2011;8:7.
44. Merrill Jr AH, Sullards MC, Allegood JC, et al. Sphingolipidomics: highthroughput, structurespecific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods. 2005;36:207-24.
45. Nagano K, Yoshida Y, Isobe T. Cell surface biomarkers of embryonic stem cells. Proteomics. 2008;8:4025-35.
46. Narisada M, Kawamoto S, Kuwamoto K, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun. 2008;377:792-6.
47. Natunen S, Satomaa T, Pitkänen V, et al. The binding specificity of the marker antibodies Tra-1-60 and Tra-1-81 reveals a novel pluripotency-associated type 1 lactosamine epitope. Glycobiology. 2011;21:1125-30.
48. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 2011;128:1860-71.
49. Pivac N, Knezević A, Gornik O, et al. Human plasma glycome in attention-deficit hyperactivity disorder and autism spectrum disorders. Mol Cell Proteomics. 2011;10:M110.004200.
50. Saito M, Kitamura H, Sugiyama K. The specificity of monoclonal antibody A2B5 to c-series gangliosides. J Neurochem. 2001;78:64-74.
51. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802-6.
52. Satomaa T, Heiskanen A, Mikkola M, et al. The N-glycome of human embryonic stem cells. BMC Cell Biol. 2009;10:42.
53. Shevinsky LH, Knowles BB, Damjanov I, et al. Monoclonal antibody to murine embryos defines a stage-specific embryonic antigen expressed on mouse embryos and human teratocarcinoma cells. Cell. 1982;30:697-705.
54. Shi T, Su D, Liu T, et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics. 2012;12:1074-92.
55. Sisu E, Flangea C, Serb A, et al. High-performance separation techniques hyphenated to mass spectrometry for ganglioside analysis. Electrophoresis. 2011;32:1591-609.
56. Smoller JW, Craddock N, et al. Cross-disorder Group of the Psychiatric Genomics Consortium, Identification of risk loci with shared effects on five major psychiatric disorders: a genomewide analysis. Lancet. 2013;381:1371-9.
57. Stanta JL, Saldova R, Struwe WB, et al. Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res. 2010;9:4476-89.
58. Sumar N, Bodman KB, Rudd PM. Lectins as indicators of disease-associated glycoforms. In: Gabius H-J, Gabius S, editors. Lectins and glycobiology. New York: Springer Laboratory; 1993. p. 158-74.
59. Sun X-L. Cellular glycomics - recent strategies and approaches. J Glycom Lipidom. 2012;2:e105.
60. Tang C, et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol. 2011;29:829-34.
61. Taniguchi N. Toward cancer biomarker discovery using the glycomics approach. Proteomics. 2008;8:3205-8.
62. Taniguchi N, Honke K, Fukuda M, et al. Handbook of glycosyltransferases and related genes. Tokyo: Springer; 2002. p. 670.
63. Thanabalasingham G, Huffman JE, Kattla JJ, et al. Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes. 2013;62:1329-37.
64. van der Zwaag B, Franke L, Poot M, et al. Gene-network analysis identifies susceptibility genes related to glycobiology in autism. PLoS One. 2009;4:e5324.
65. Volpi N, Galeotti F, Yang B, et al. Analysis of glycosaminoglycan-derived, precolumn, 2-aminoacridone-labeled disaccharides with LC-fluorescence and LC-MS detection. Nat Protoc. 2014;9:541-58.
66. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, Van Kamp GJ, Paul MA, van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favourably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18:574-83.
67. Wade A, Robinson AE, Engler JR, et al. Proteoglycans and their roles in brain cancer. FEBS J. 2013;280:2399-417.
68. Wandall HH, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010;70:1306-13.
69. Wang CC, Huang YL, Ren CT, Lin CW, Hung JT, Yu JC, et al. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci U S A. 2008;105(33):11661-6.
70. Wang P, Qu J, Wu MZ, et al. "TET-on" pluripotency. Cell Res. 2013;23:863-5.
71. Yuki N, Hartung H-P. Guillain-Barré syndrome. N Eng J Med. 2012;366:2294-304.
72. Zaia J. Mass spectrometry and glycomics. OMICS. 2010;14:401-18.
73. Zauner G, Koeleman CA, Deelder AM, et al. Mass spectrometric O-glycan analysis after combined O-glycan release by β-elimination and 1-phenyl-3-methyl-5-pyrazolone labeling. Biochim Biophys Acta. 2012;1820:1420-8.
74. Zhang Y, Yin H, Lu H. Recent progress in quantitative glycoproteomics. Glycoconj J. 2012;29:249-58.